罗氟司特价格是多少？

Roflumilast is a phosphodiesterase-4 (PDE4) inhibitor primarily used to treat inflammation associated with chronic obstructive pulmonary disease (COPD). The drug was developed by AstraZeneca Pharmaceutical Co., Ltd. There is a significant price difference between the original drug and the generic drug. This article compares the price data of major global markets in detail, analyzes the current status of domestic listings, and explains the medical insurance reimbursement situation to provide patients with a comprehensive economic reference for medication.

What is the price of the original drug and the generic version of roflumilast?

There are significant differences in pricing in different countries and regions, and the price gap between the original version and the generic version can be several times greater.

Original drug price

The original drug produced by AstraZeneca in the UK is priced at US$233 in a 500μg*30-piece package in the German market, and US$391 in a 90-piece package. The product with the same specifications in the Hong Kong market is priced at US$134, which is 42% cheaper than the German version.

Prices of generic drugs in India

The price of 500μg*30 tablets of generic drugs produced by Cipla in India is about US$45. The price of generic drugs in India is only 1/3 to 1/5 of the original drugs.

The price difference is mainly due to R&D costs, production technology and local consumption levels. Patients can choose a suitable version according to their needs.

Roflumilast’s domestic marketing status

Currently, roflumilast has not yet received marketing approval from the China National Medical Products Administration, and domestic patient access channels are limited.

Approval Progress

Roflumilast is still in the domestic clinical trial stage and a marketing application has not yet been submitted. It is expected that it may be approved for marketing in the next few years.

Acquisition methods

Domestic patients mainly obtain drugs through three methods: cross-border medical e-commerce purchase, special outpatient clinics of international hospitals, and in-person overseas purchase. A formal prescription is required before purchasing drugs.

Purchase risks

Drugs purchased through informal channels have risks of quality problems. It is recommended to choose a qualified cross-border medical platform and keep the complete proof of purchase.

Before it is officially launched in the country, patients need to carefully choose purchasing channels to ensure the quality of the drug.

Roflumilast’s medical insurance reimbursement situation

Since it has not yet been launched in China, roflumilast does not currently qualify for medical insurance reimbursement, and patients need to pay the full amount out of their own pocket.

International medical insurance situation

In countries such as Germany and the United Kingdom, roflumilast has been included in the scope of medical insurance reimbursement, and the patient out-of-pocket ratio is about 20%-30%. In the United States, commercial insurance coverage is required.

Domestic Future Outlook

If it is approved for marketing in the country in the future, it will need to go through pharmacoeconomic evaluation and medical insurance negotiation before it can be included in reimbursement.

Current cost solutions

The overseas medical provisions of some commercial insurance may cover related costs. Patients can consult their insurance company for specific reimbursement policies.

In the absence of medical insurance, choosing more cost-effective generic drugs is a feasible solution to reduce the financial burden.